No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA The Company secured collaborative research funding
Form 7 Monthly Progress Report January 2024 Name of Listed Issuer: Trading Symbol: Number of
Vancouver, British Columbia – (February 28, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”)
Vancouver, British Columbia – (February 26, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE:
Form 7 Monthly Progress Report January 2024 Name of Listed Issuer: Trading Symbol: Number of
1 604 370 0779
130 3851 Shell Road
Richmond BC
Canada V6X 2W2